OBJECTIVE： To investigate the utilization and trend of endocrine therapeutic drugs after breast cancer surgery， and to provide reference for rational drug use in clinic. METHODS： In retrospective study， the data of endocrine therapeutic drugs use in outpatients after breast cancer in a Third Grade Class A Hospital during 2014-2016 was calculated， sorted and analyzed statistically.  RESULTS： The age of outpatients receiving endocrine therapy after breast cancer ranged from ＞40 to 60. Among endocrine therapeutic drugs used within 3 years， 3 kinds of them were aromatase inhibitor （AI）， 3 kinds were anti-estrogen and 2 kinds were gonadotropin releasing hormone （GnRH） analogues. The amount of Toremifene citrate tablets （imported） in prescription was much more than the others. The proportion of anti-estrogen drugs alone in prescription was the highest （81.11％）. The AI and GnRH analogues were mostly used in drug combination prescription， and commonly combined with anti-osteoporosis drugs. The comsuption sum of endocrine therapeutic drugs was increased year by year， increasing by 52.48％ in 2015， 40.60％ in 2016. The consumption sum of AI ranked the highest proportion among three categories of endocrine drugs （44.71％， 48.62％， 48.62％， each year respectively）. The consumption sum of imported drugs was significantly higher than that of domestic drugs. The consumption sum of Toremifene citrate tablets （imported） increased continuously in 3 years， and took the first place in 2016. The consumption sum of Leuprorelin acetate microspheres for injection （imported） had the largest growth rate when applied to the clinic. Top types in the list of DDC were all imported types； Fulvestrant injection （imported） ranked top 1， and Tamoxifen citrate tablet （domestic） was the bottom of the list. DDDs of endocrine therapeutic drugs also increased year by year， among which Toremifene citrate tablets， Tamoxifen citrate tablets， Anastrozole tablets and Letrozol tablets ranked top 4 places during the 3 years， while Tamoxifen citrate tablets DDDs decreased year by year. B/A values of these drugs were between 0.25 and 9.00. B/A values of domestic varieties were basically more than or equal to 1， of which Tamoxifen citrate tablets was the largest； B/A values of the imported varieties were basically less than or equal to 1. CONCLUSIONS： The consumption sum of endocrine therapeutic drugs after breast cancer surgery increased year by year in 3 years， and DDDs is also increasing year by year. The imported drugs took up the dominant place. Toromiphene citrate tablets had replaced Tamoxifen citrate tablets as the first choice of endocrine therapeutic drugs in the hospital. The frequency of AI and GnRH analogues use had also increased. And the combination of 2 kinds of endocrine therapeutic drugs and endocrine therapeutic drugs combined with anti-osteoporosis drug had become a trend of clinical treatment. The choice of therapeutic drugs should take into account of effectiveness， safety， economics， cost and therapeutic efficacy， so as to guarantee the greatest benefit of the patient.